// App-Quantinova.ai

4078 : KRAS mutation status is associated with stromal inactivation in colorectal cancer and predicts poor response to neoadjuvant chemoradiotherapy

Researchers

Presenter

  • Raphael Pelossof

Principal Investigators

  • Moshe Elkatebts

  • Oliver Chow

  • Lauren Fairchild

  • Kevin ORourke

  • Jesse J. Smith

  • Chin-Tung Chen

  • Samuel Brook

  • Maurizio Scaltriti

  • Jinru Shia

  • Philip Paty

  • Christina Leslie

  • Scott Lowe

  • Jose Baselga

  • Julio Garcia-Aguilar

Medical Centers

  • Memorial Sloan Kettering, New York, NY

  • Ben Gurion University, Beer Sheva, Israel

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Weill Cornell, New York, NY

Locations

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Familial adenomatous polyposis

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Adenomatous Polyposis Coli

  • C-C Motif Chemokine Ligand 20

  • Periostin

  • Tumor protein p53

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved